ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, today announced its financial results for the first quarter ended March 31, 2008. The Company held cash, cash equivalents, short-term and long-term investments of $46.3 million at March 31, 2008, as compared to $50.3 million at December 31, 2007.
